Due to the critical role of Tregs in prevention of auto-immune-related diseases, approaches that specifically deplete intratumoral Tregs or that only partially deplete Tregs, by targeting for example CCR8, OX-40, CCR4 and CD2513,33,35,37,73, may be more feasible for use in cancer patients. The gene discussed is CCR4; the disease is cancer.